Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|17|4|347-364

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.17, Iss.4, 2016-03, pp. : 347-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia

By Siuciak Judith A   Strick Christine A  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 7, 2007-07 ,pp. : 1001-1009

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

By De LaVega Alfonso J   Derk Chris T  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 1, 2009-01 ,pp. : 23-29

Informa Healthcare

Access to resources Recommend Favorite

New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)

By  

Current Medicinal Chemistry, Vol. 23, Iss. 12, 2016-05 ,pp. : 1239-1249

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension: A Meta-Analysis

By Jin Bo   Luo Xin-Ping   Ni Huan-Chun   Shi Hai-Ming  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 259-265

Adis International

Access to resources Recommend Favorite

Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension

By  

Current Medicinal Chemistry, Vol. 14, Iss. 6, 2007-03 ,pp. : 719-733

Bentham Science Publishers

Access to resources Recommend Favorite